Attached is my post to a person that said a Term Sheet could or would be nice to see in the next few days or weeks. I call them as I see them and this is my opinion. Could have many holes shot in my thinking but I listen to alternative ideas openly so differing opinions welcomed:
Why would you think a BP would sign off on a partnership for Brilacidin not knowing if it will be a success in the human trial? And if it didsign a deal prior to the end of the trial, why would they give IPIX a proper amount of funds for those rights? BP is not known or needs taking such risks - they have been allowed to pay pennies on the dollar for good drugs due to the BS rules of getting a drug to market. IPIX is changing that as IMO we are going to see some major investigational grants soon awarded by various government and non-government bodies to fully explore the whole package that is Brilacidin. I also think Brilacidin sees some serious income from world governments buying the IV Brilacidin bags in the near future for emergency use for CV19. That takes care of the money problems and IPIX can retain full rights to B until its true value is made known.
So IMO a deal now would be insane on the part of either BP or IPIX.
If I was in Leo's shoes I would have a successful CV19 trial AND a successful B-Ulcerative Colitis trial in my pocket before I would allow any BP to start ponying up values for Brilacidin.
I also don't see what a PR at this time would accomplish in regards to the trial being fully enrolled or when it started. The +/- in timing is only a week or two so very little accomplished by making dates known and I certainly don't want him naming any sites of the trials. If they want to throw some info into a regulatory filing, fine, but a separate PR at this time not needed IMO.
CV19 is big, but it is just a small cog in the overall value of the entire Brilacidin platform. As each small cog comes to pass the value of the Brilacidin platform keeps rising so by the time a deal is made for the platform the price of IPIX IMO should be near double digits so that the buyout or partnership rights are extremely substantial. Way too early in the game at this time for such to happen.
It is apparent that my entire view is based on IPIX dealing from a position of strength, strength based on proven clinical trial data, and if that doesn't come to pass my ideas go up in smoke. If one doubts Brilacidin, they sell/deal for pennies now but if one believes Brilacidin is truly the monster drug many feel it is, then taking our time to get the data and raise the value seems quite prudent.
Why would you think a BP would sign off on a partnership for Brilacidin not knowing if it will be a success in the human trial? And if it didsign a deal prior to the end of the trial, why would they give IPIX a proper amount of funds for those rights? BP is not known or needs taking such risks - they have been allowed to pay pennies on the dollar for good drugs due to the BS rules of getting a drug to market. IPIX is changing that as IMO we are going to see some major investigational grants soon awarded by various government and non-government bodies to fully explore the whole package that is Brilacidin. I also think Brilacidin sees some serious income from world governments buying the IV Brilacidin bags in the near future for emergency use for CV19. That takes care of the money problems and IPIX can retain full rights to B until its true value is made known.
So IMO a deal now would be insane on the part of either BP or IPIX.
If I was in Leo's shoes I would have a successful CV19 trial AND a successful B-Ulcerative Colitis trial in my pocket before I would allow any BP to start ponying up values for Brilacidin.
I also don't see what a PR at this time would accomplish in regards to the trial being fully enrolled or when it started. The +/- in timing is only a week or two so very little accomplished by making dates known and I certainly don't want him naming any sites of the trials. If they want to throw some info into a regulatory filing, fine, but a separate PR at this time not needed IMO.
CV19 is big, but it is just a small cog in the overall value of the entire Brilacidin platform. As each small cog comes to pass the value of the Brilacidin platform keeps rising so by the time a deal is made for the platform the price of IPIX IMO should be near double digits so that the buyout or partnership rights are extremely substantial. Way too early in the game at this time for such to happen.
It is apparent that my entire view is based on IPIX dealing from a position of strength, strength based on proven clinical trial data, and if that doesn't come to pass my ideas go up in smoke. If one doubts Brilacidin, they sell/deal for pennies now but if one believes Brilacidin is truly the monster drug many feel it is, then taking our time to get the data and raise the value seems quite prudent.
6
